Connecting Markets. Empowering People. Transforming Economies.
NiDCC

Insights

Insights and Intelligence

Home Insights and Intelligence

Intelligence for decisions, partnerships and market expansion.

Economic reporting from around the world, filtered to the sectors and policy areas our members build in — part of the same intelligence stream behind the Global Economic Outlook and NiDCC's market reports.

MBX Biosciences upgraded to Buy on strong Phase 2 data and promising Phase 3 outlook for hypoparathyroidism drug.

life_sciences — September 23, 2026, 8:20 PM · Pluang

MBX Biosciences upgraded to Buy on strong Phase 2 data and promising Phase 3 outlook for hypoparathyroidism drug.

MBX Biosciences received a "Buy" rating upgrade after strong Phase 2 results for its hypoparathyroidism drug, canvuparatide, which offers once-weekly dosing and high efficacy, positioning it to potentially achieve blockbuster revenues. The company also has an early-stage obesity treatment pipeline, significant cash reserves, and several upcoming catalysts, suggesting substantial upside potential despite inherent risks in drug development. This upgrade reflects confidence in its lead drug's market potential and the company's overall financial health and strategic pipeline.

Explore more
A share grant led to a tax-related sale: Legend Biotech (LEGN) CFO received 19,676 shares and sold 5,430.

life_sciences — September 23, 2026, 8:20 PM · Stock Titan

A share grant led to a tax-related sale: Legend Biotech (LEGN) CFO received 19,676 shares and sold 5,430.

Legend Biotech's CFO, Carlos E. Santos, received a grant of 19,676 Ordinary Shares on September 21, 2026. On the same day, he sold 5,430 of these shares at a weighted average price of $9.14 per share to cover withholding tax obligations related to the vesting of restricted share units. This transaction is categorized as a neutral filing impact with a negative sentiment due to the sale.

Explore more
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

life_sciences — September 23, 2026, 8:19 PM · Yahoo Finance

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio has submitted a New Drug Application (NDA) to the U.S. FDA for seralutinib, intended for the treatment of pulmonary arterial hypertension (PAH). This significant milestone is supported by data from the Phase 3 PROSERA Study and the Phase 2 TORREY Study. The FDA will now review the application to determine its acceptance for filing, bringing Gossamer Bio closer to potentially offering a new therapy for PAH patients.

Explore more